Plant Name: Brassica juncea
Taxonomic Information:
Plant ID: NPO29007
Plant Latin Name: Brassica juncea
Taxonomy Genus: Brassica
Taxonomy Family: Brassicaceae
Plant External Links:
NCBI TaxonomyDB:
3707
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
China; Philippines; India; RussiaTraditional Medicine System:
Indian Folk; TCM; Unani; Ayurveda; SiddhaMedicinal Functions:
Anodyne; Antibiotic; Aperient; Diuretic; Emetic; Galactogogue; Rubefacient; Stimulant
Geographical Distribution:
India; Philippines; China; Russia
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; | |
| GRM1; GRM8; | |
| TSHR; NPSR1; | |
| BLM; MIF; PKM; ALOX12; HSD17B2; HSD17B10; NOX4; POLB; | |
| GRIA4; GRIA2; GRIK3; GRIK5; GRIK1; | |
| TRPA1; | |
| AXL; MET; FLT3; CDK1; PIM1; KDR; IGF1R; AURKB; | |
| CA12; CA7; | |
| TYR; | |
| KDM4E; | |
| MMP9; MMP1; MMP2; | |
| AHR; NFKB1; | |
| FUT7; | |
| SLC1A1; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | MIF | Macrophage migration inhibitory factor | P14174 | CHEMBL2085 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Ionotropic glutamate receptor | GRIA4 | Glutamate receptor ionotropic, AMPA 4 | P48058 | CHEMBL3190 |
| Ionotropic glutamate receptor | GRIA2 | Glutamate receptor ionotropic, AMPA 2 | P42262 | CHEMBL4016 |
| Ionotropic glutamate receptor | GRIK3 | Glutamate receptor ionotropic kainate 3 | Q13003 | CHEMBL3684 |
| Ionotropic glutamate receptor | GRIK5 | Glutamate receptor ionotropic kainate 5 | Q16478 | CHEMBL2675 |
| Ionotropic glutamate receptor | GRIK1 | Glutamate receptor ionotropic kainate 1 | P39086 | CHEMBL1918 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| SLC superfamily of solute carriers | SLC1A1 | Excitatory amino acid transporter 3 | P43005 | CHEMBL2721 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family C GPCR) | GRM1 | Metabotropic glutamate receptor 1 | Q13255 | CHEMBL3772 |
| Small molecule receptor (family C GPCR) | GRM8 | Metabotropic glutamate receptor 8 | O00222 | CHEMBL3228 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005215; transporter activity | GO:0005234; extracellularly glutamate-gated ion channel activity | 5.507E-10 | 2.216E-06 | GRIA2, GRIA4, GRIK1, GRIK3, GRIK5 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.468E-10 | 2.323E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP3A4, NOX4 |
| BP | GO:0009987; cellular process | GO:0035235; ionotropic glutamate receptor signaling pathway | 3.079E-09 | 7.449E-06 | GRIA2, GRIA4, GRIK1, GRIK3, GRIK5 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.868E-09 | 1.060E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.404E-08 | 5.641E-05 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0005215; transporter activity | GO:0015277; kainate selective glutamate receptor activity | 1.099E-07 | 7.721E-05 | GRIK1, GRIK3, GRIK5 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.362E-07 | 8.772E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| MF | Unclassified; | GO:0004872; receptor activity | 1.370E-07 | 8.772E-05 | ADORA3, AHR, AXL, FLT3, GRIA2, GRIA4, GRIK1, GRIK3, GRIK5, GRM1, GRM8, IGF1R, KDR, MET, NPSR1, TSHR |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.009E-07 | 1.182E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.195E-07 | 1.207E-04 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.322E-07 | 1.972E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP3A4, NOX4 |
| BP | GO:0023052; signaling | GO:0060079; excitatory postsynaptic potential | 4.893E-07 | 2.174E-04 | GRIA2, GRIA4, GRIK1, GRIK3, GRIK5 |
| BP | GO:0009987; cellular process | GO:0007196; adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway | 9.175E-07 | 3.275E-04 | GRIK3, GRM1, GRM8 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.600E-06 | 5.234E-04 | ALOX12, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.392E-06 | 7.134E-04 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.392E-06 | 7.134E-04 | CYP1A2, CYP2C9, CYP3A4 |
| CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 7.564E-06 | 1.842E-03 | AHR, GRIA2, GRIA4, GRIK5, GRM1, IGF1R, TSHR |
| BP | GO:0023052; signaling | GO:0051966; regulation of synaptic transmission, glutamatergic | 9.727E-06 | 2.229E-03 | GRIK1, GRIK3, GRM1, GRM8 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.519E-05 | 3.243E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.892E-05 | 3.923E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 2.368E-05 | 4.731E-03 | ALOX12, CDK1, FLT3, IGF1R, KDR, MIF, MMP2, MMP9, PIM1, TSHR |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 2.666E-05 | 5.137E-03 | AXL, CDK1, FLT3, PKM |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 2.829E-05 | 5.404E-03 | BLM, IGF1R, MMP2, NFKB1, NOX4, PKM, TSHR |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.034E-05 | 5.695E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005215; transporter activity | GO:0004971; AMPA glutamate receptor activity | 3.034E-05 | 5.695E-03 | GRIA2, GRIA4 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 5.049E-05 | 8.867E-03 | CYP1A1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0051260; protein homooligomerization | 5.843E-05 | 9.787E-03 | BLM, HSD17B10, MIF, PKM, SLC1A1, TRPA1 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09156 Nervous system | hsa04724 | Glutamatergic synapse | 1.298E-10 | 1.778E-08 | GRIA2, GRIK5, SLC1A1, GRM8, GRIK3, GRIK1, GRM1, GRIA4 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 7.641E-09 | 5.234E-07 | GRIA2, GRIK5, ADORA3, GRM8, GRIK3, GRIK1, TSHR, GRM1, GRIA4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.713E-07 | 7.822E-06 | CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.479E-07 | 1.877E-05 | CYP2C9, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 4.358E-06 | 9.951E-05 | HSD17B2, CYP1A1, CYP1B1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 9.809E-07 | 2.688E-05 | CYP2C9, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 2.343E-05 | 4.012E-04 | FLT3, MMP1, MMP2, MET, MMP9, NFKB1, IGF1R |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.251E-05 | 2.448E-04 | CYP2C9, CYP1A2, CYP1A1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 8.073E-05 | 1.005E-03 | MMP2, KDR, MMP9, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 4.564E-05 | 6.253E-04 | FLT3, MMP9, MET, NFKB1, IGF1R |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 2.872E-04 | 2.623E-03 | CYP2C9, FUT7, PKM, HSD17B2, CYP1A2, CYP1A1, ALOX12, CYP3A4, TYR, HSD17B10 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 9.273E-05 | 1.053E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.488E-05 | 5.309E-04 | CYP2C9, CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 2.675E-04 | 2.618E-03 | FLT3, PIM1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 9.989E-05 | 1.053E-03 | MMP1, MMP2, MMP9 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 4.719E-04 | 3.403E-03 | PIM1, CYP1B1, MMP9, MET, NFKB1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04730 | Long-term depression | 3.115E-04 | 2.667E-03 | GRIA2, GRM1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 4.314E-04 | 3.403E-03 | PKM, FLT3, MET |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 9.456E-04 | 6.169E-03 | GRIA2, NFKB1, TSHR, GRIA4 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.056E-03 | 6.574E-03 | POLB, PKM, CDK1, NFKB1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 4.703E-04 | 3.403E-03 | CYP2C9, CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.424E-03 | 7.806E-03 | MMP2, PIM1, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.537E-03 | 8.099E-03 | KDR, MET, NFKB1, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.345E-03 | 7.806E-03 | MMP2, MMP9, GRM1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04723 | Retrograde endocannabinoid signaling | 1.424E-03 | 7.806E-03 | GRIA2, GRM1, GRIA4 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 6.299E-04 | 4.315E-03 | CA12, CA7 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; TYR; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; MMP2; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | MIF; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; ADORA3; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | GRM1; CDK1; IGF1R; TRPA1; GRIK1; PKM; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | GRIA2; GRIA4; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| NA: NA | HIV infections | NA | AHR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | GRM1; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; MMP2; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | GRIK1; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; NFKB1; FLT3; ADORA3; MMP9; MMP2; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | GRM1; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; MMP9; PKM; MMP2; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GRM1; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Refractory autoimmune diseases | D84.9, M35.9 | MIF; |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | GRIK1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | GRM1; NPSR1; GRIK1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | GRM1; GRIK1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MIF; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
